VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer

Lung Cancer

Volumn 64, Issue 2, 2009, Pages 219-225

  Dalaveris, Eleftherios ^a   Kerenidi, Theodora ^a   Katsabeki Katsafli, Alexandra ^a   Kiropoulos, Theodoros ^a   Tanou, Kalliopi ^a   Gourgoulianis, Konstantinos I ^a   Kostikas, Konstantinos ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

8 Isoprostane; Biomarkers; Exhaled breath condensate; Lung cancer; Oxidative stress; TNF ; VEGF

Indexed keywords

8 ISOPROSTANE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EXPIRED AIR; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; BREATH TESTS; DINOPROST; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXHALATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63049111164     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.08.015     Document Type: Article

References (37)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Kaminska J., Kowalska M., Kotowicz B., Fuksiewicz M., Glogowski M., Wojcik E., et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor. Oncology 70 (2006) 115-125
3. Boldrini L., Calcinai A., Samaritani E., Pistolesi F., Mussi A., Lucchi M., et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 83 (2000) 480-486
4. Papaioannou A.I., Kostikas K., Kollia P., and Gourgoulianis K.I. Clinical implications for vascular endothelial growth factor in the lung: friend or foe?. Respir Res 7 (2006) 128
5. Takigawa N., Segawa Y., Fujimoto N., Hotta K., and Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 18 (1998) 1251-1254
6. Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., and Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 24 (2006) 492-496
7. Chung-man Ho J., Zheng S., Comhair S.A., Farver C., and Erzurum S.C. Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res 61 (2001) 8578-8585
8. Gromadzinska J., and Wasowicz W. The role of reactive oxygen species in the development of malignancies. Int J Occup Med Environ Health 13 (2000) 233-245
9. Katsabeki-Katsafli A., Kerenidi T., Kostikas K., Dalaveris E., Kiropoulos T.S., Gogou E., et al. Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. Lung Cancer 60 (2008) 271-276
10. Zieba M., Nowak D., Suwalski M., Piasecka G., Grzelewska-Rzymowska I., Tyminska K., et al. Enhanced lipid peroxidation in cancer tissue homogenates in non-small cell lung cancer. Monaldi Arch Chest Dis 56 (2001) 110-114
11. Kharitonov S.A., and Barnes P.J. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 163 (2001) 1693-1722
12. Horvath I., Hunt J., Barnes P.J., Alving K., Antczak A., Baraldi E., et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 26 (2005) 523-548
13. Koutsokera A., Loukides S., Gourgoulianis K.I., and Kostikas K. Biomarkers in the exhaled breath condensate of healthy adults: mapping the path towards reference values. Curr Med Chem 15 (2008) 620-630
14. Carpagnano G.E., Resta O., Foschino-Barbaro M.P., Gramiccioni E., and Carpagnano F. Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int J Biol Markers 17 (2002) 141-145
15. Carpagnano G.E., Spanevello A., Curci C., Salerno F., Palladino G.P., Resta O., et al. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients. Oncol Res 16 (2007) 375-381
16. Carpagnano G.E., Foschino-Barbaro M.P., Resta O., Gramiccioni E., and Carpagnano F. Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer. Oncology 66 (2004) 180-184
17. Carpagnano G.E., Foschino-Barbaro M.P., Spanevello A., Resta O., Carpagnano F., Mule G., et al. 3p Microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. Am J Respir Crit Care Med 177 (2008) 337-341
18. Carpagnano G.E., Foschino-Barbaro M.P., Mule G., Resta O., Tommasi S., Mangia A., et al. 3p Microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med 172 (2005) 738-744
19. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
20. Mantovani G., Maccio A., Pisano M., Versace R., Lai P., Esu S., et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer 71 (1997) 724-731
21. De Vita F., Orditura M., Auriemma A., Infusino S., and Catalano G. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res 17 (1998) 413-417
22. Matsuyama W., Hashiguchi T., Mizoguchi A., Iwami F., Kawabata M., Arimura K., et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 118 (2000) 948-951
23. Volm M., Koomagi R., and Mattern J. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 19 (1999) 651-655
24. Beinert T., Binder D., Oehm C., Ziemer S., Priem F., Schweigert M., et al. Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?. Eur J Med Res 4 (1999) 328-334
25. Brattstrom D., Bergqvist M., Hesselius P., Larsson A., Lamberg K., Wernlund J., et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 37 (2002) 57-63
26. Cheng D., Rodriguez R.M., Perkett E.A., Rogers J., Bienvenu G., Lappalainen U., et al. Vascular endothelial growth factor in pleural fluid. Chest 116 (1999) 760-765
27. Saji H., Nakamura H., Awut I., Kawasaki N., Hagiwara M., Ogata A., et al. Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg 9 (2003) 295-300
28. Bremnes R.M., Camps C., and Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51 (2006) 143-158
29. Brattstrom D., Bergqvist M., Hesselius P., Larsson A., Wagenius G., and Brodin O. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 43 (2004) 55-62
30. Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., and Topuz E. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 24 (2006) 576-580
31. Kaya A., Ciledag A., Gulbay B.E., Poyraz B.M., Celik G., Sen E., et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 98 (2004) 632-636
32. Nagy J.A., Vasile E., Feng D., Sundberg C., Brown L.F., Detmar M.J., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196 (2002) 1497-1506
33. Baraldi E., Ghiro L., Piovan V., Carraro S., Ciabattoni G., Barnes P.J., et al. Increased exhaled 8-isoprostane in childhood asthma. Chest 124 (2003) 25-31
34. Kostikas K., Papatheodorou G., Psathakis K., Panagou P., and Loukides S. Oxidative stress in expired breath condensate of patients with COPD. Chest 124 (2003) 1373-1380
35. Montuschi P., Corradi M., Ciabattoni G., Nightingale J., Kharitonov S.A., and Barnes P.J. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 160 (1999) 216-220
36. Zieba M., Suwalski M., Kwiatkowska S., Piasecka G., Grzelewska-Rzymowska I., Stolarek R., et al. Comparison of hydrogen peroxide generation and the content of lipid peroxidation products in lung cancer tissue and pulmonary parenchyma. Respir Med 94 (2000) 800-805
37. de Castro J., Hernandez-Hernandez A., Rodriguez M.C., Llanillo M., and Sanchez-Yague J. Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer. Cancer Invest 24 (2006) 339-345